Will compounded Semaglutide still be available in the future
In the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), mean weight loss at 72 weeks varied by dose: 15.0% at 5 mg, 19.5% at 10 mg, and 22.5% at 15 mg
This is because ketone body defects inhibit lipid oxidation by inhibiting -hydroxybutyrylation, which prevents the metabolic flow from acetyl-coenzyme A delivery to the ketone bodies (72), thereby echoing the previously discussed inhibition of cardiac proliferation and regeneration by fatty acid metabolism
However, it may also be used off-label for weight management
For a person starting at 160 lbs, the difference between 21.1% and 24.2% is about 5 lbs
1v,w and Extended Data Fig